Pediatric Acute Lymphoblastic Leukemia: Regimen components…Consolidation…For CRLF2+ or CRLF2- with JAK2 fusions, EPOR rearrangement, SH2B3 alterations, IL7R insertions/deletions: cyclophosphamide, cytarabine, 6-MP, vincristine, pegaspargase + ruxolitinib; IT therapy: methotrexate

Patients aged 1-21 years at time of diagnosis with HR B-ALL... cohort A = CRLF2-R JAK-mutant, MRD+; B = CRLF2-R JAK-wild-type, MRD+; C = other JAK pathway alterations, MRD+, D = any CRLF2-R or JAK pathway alteration, MRD-. Patients commenced treatment on the INCB18424-269/AALL1521 study at consolidation with ruxolitinib...These findings demonstrate safety and tolerability of ruxolitinib in combination with intensive multi-agent chemotherapy in children and AYAs with newly-diagnosed HR CRLF2-R/JAK pathway-mutant Ph-like ALL...